Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RESP301 + isoniazid + rifampin + pyrazinamide + ethambutol
- Development stage
- Unknown
- Lead developer
- 30 Technology
- Modality
- Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
- Administration
- Inhalation, Oral
01
Overview
This combination consists of RESP301, a nitric oxide (NO)-generating inhaled solution, together with four first-line oral anti-tuberculosis drugs: isoniazid, rifampin, pyrazinamide, and ethambutol. RESP301 delivers inhaled NO directly to the respiratory tract, exerting direct antimicrobial activity (antiviral and antibacterial) and enhancing host defenses. Isoniazid inhibits mycolic acid synthesis in Mycobacterium tuberculosis. Rifampin blocks bacterial RNA polymerase. Pyrazinamide is bactericidal against replicating and dormant mycobacteria. Ethambutol impairs cell wall synthesis by inhibiting arabinosyl transferases. This combination is under clinical investigation for the treatment of pulmonary tuberculosis, with RESP301 adding a novel, inhaled mechanism to standard oral TB therapy[1][2][4].
- Brand names
- RESP301RESP-301RESP 301
- Other names
- RESP301 plus HRZERESP-301 plus HRZERESP 301 plus HRZEnitric oxide-generating solution + HRZE
02
Targets
rpoB (DNA-directed RNA polymerase subunit beta)InhAembB (Arabinosyltransferase EmbB)PncA (Nicotinamidase)Aspartate decarboxylase
Beyond the preview
Go deeper on RESP301 + isoniazid + rifampin + pyrazinamide + ethambutol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RESP301 + isoniazid + rifampin + pyrazinamide + ethambutol.